- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Latest Advances and Therapies for HER2+ NSCLC
Panelists discuss how recent clinical trial results for emerging HER2-directed therapies, including findings from the SOHO-01 study, inetetamab/pyrotinib combination study, and Beamion LUNG-1, are shaping the future landscape of NSCLC treatment, while also highlighting other noteworthy developments presented at this year’s World Conference on Lung Cancer.
EP: 1.Introduction and Current Landscape of HER2 in NSCLC
EP: 2.Safety and Efficacy of HER2-Directed ADCs for NSCLC
EP: 3.Treatment Considerations for Patients With HER2+ NSCLC
EP: 4.Latest Advances and Therapies for HER2+ NSCLC
EP: 5.Unmet Needs and Clinical Considerations for HER2+ NSCLC
EP: 6.Integrating HER2-Directed Therapies Into Standard Care for NSCLC
EP: 7.HER2- Mutation Testing Considerations and Timing
EP: 8.Factors Impacting Use of HER2 Therapies for NSCLC
EP: 9.Incorporating Real-World Evidence for HER2+ NSCLC
EP: 10.Key Takeaways on the Future of HER2 in NSCLC
EP: 11.Real-World Outcomes in HER2-Positive NSCLC
EP: 12.Managing Treatment Challenges in HER2-Directed Therapies
EP: 13.Emerging Horizons in HER2-Directed NSCLC Treatments
EP: 14.Patient Selection and Personalized Treatment Strategies
EP: 15.Navigating Healthcare Access and Decision-Making
Video content above is prompted by the following:
- Several HER2-directed therapies are currently in development. Could you discuss the recent clinical trial results for emerging agents, such as those from the SOHO-01 study, the inetetamab/pyrotinibcombination study, and the Beamion LUNG-1 study, and what implications these findings might have for the future landscape of HER2-directed therapies in NSCLC?
- (Heymach) What other notable data from this year’s World Conference on Lung Cancer are you most excited about?
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
